Sanguine Resources

News | Events | Case Studies | Spotlight

Considerations for Feasibility for Translational Research

Considerations for Feasibility for Translational Research For many researchers, considering the feasibility of a translational study with Sanguine Biosciences is a crucial yet challenging step. The proposed study they submit might not be possible based on real-world evidence or Sanguine’s service offerings, requiring them to modify their criteria.

Monitoring Systemic Lupus Erythematosus Longitudinally

Systemic lupus erythematosus (SLE), also known as lupus, is a chronic autoimmune disease caused by random or inherited mutations in various genes of the immune system. It affects the skin, joints, kidneys, brain, and almost every other organ. People suffering from SLE experience inflammation in the connective tissues that provide strength and flexibility to structures throughout the body.

Recovered Coronavirus Patient Donates Blood To Help Vaccine, Treatment Research

WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.

PODCAST: The Bio Report: Bringing the Trial to the Patient

One of the challenges to securing the participation of patients in clinical trials can be simple geography. Sanguine Biosciences is seeking to tear down that barrier to participation by using mobile technology to bring clinical trials to patients. The company recently partnered with Vir Biotechnology to complete a COVID-19 clinical study aimed at better understanding the biology of the disease by sending healthcare personnel to collect blood samples from patients at their homes.

COVID-19: Navigating the Pandemic

  COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. In this Sanguine Speaker Series (3) virtual fireside chat, we will discuss: Response efforts to the current COVID-19 pandemic How does the race for the cure affect the hundreds of other drugs in development COVID-19’s potential impact on the global pharmaceutical market?

Sickle Cell Disease

A Novel Non-Covalent Modulator of Hemoglobin Improves Anemia and Reduces Sickling in a Mouse Model of Sickle Cell Disease. Speaker: Kelly M. Knee, PhD, Senior Principal Scientist, Rare Disease Researcher Unit, Pfizer Sickle cell disease is a severe genetic disorder caused by a single point mutation on the β-chain of adult hemoglobin (Hb A), β6 Glu→Val (Hb S).

COVID-19: Navigating the Pandemic

COVID-19 has spread to more than 60 countries, causing tens of thousands of illnesses and thousands of deaths. Pharma companies, biotechs, governments, academic institutions, nonprofits and others are all racing to develop a treatment, a cure and a vaccine. Moderator Craig Lipset – Independent Advisor, Former Head of Clinical Innovation, Pfizer Transcript John: We would like to welcome you to the Sanguine Speaker Series Webinar on COVID-19; Navigating the Pandemic.